Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions
The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Medical technology company Becton, Dickinson and Company (NYSEBDX)
will be announcing earnings results tomorrow before market open. Here’s what to look for.
Medical device company Boston Scientific (NYSEBSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next quarter’s revenue was optimistic at $4.55 billion at the midpoint, 2.5% above analysts’ estimates. Its non-GAAP profit of $0.70 per share was 6.6% above analysts’ consensus estimates.
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
For investors seeking high-potential stocks priced under $2, several companies stand out due to their innovative offerings, upcoming developments, or strategic positioning in the market. Here’s a look at five noteworthy companies to watch in addition to Sana Biotechnology (NASDAQSANA) and CS Diagnostics Corp. (OTCQB: CSDX) in January 2025.
Boston Scientific to acquire Bolt Medical for $600 million upfront plus milestones. Bolt's IVL platform addresses coronary and peripheral artery disease.
